Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

被引：0
|
作者：
Hisamitsu Ishihara
Susumu Yamaguchi
Ikko Nakao
Seitaro Asahina
Taishi Sakatani
机构：
[1] Nihon University School of Medicine,Division of Diabetes and Metabolic Diseases
[2] Astellas Pharma Inc.,undefined
来源：
Diabetology International | 2019年 / 10卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Insulin; Ipragliflozin; Sodium–glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：37 / 50
页数：13
相关论文
共 50 条
  • [21] Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase
    Kaku, Kohei
    Mori, Mikiko
    Kanoo, Tatsuhiro
    Katou, Masafumi
    Seino, Yutaka
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (15) : 2121 - 2130
  • [22] Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension
    Kadowaki, T.
    Kondo, K.
    DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 418 - 425
  • [23] Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, double blind placebo-controlled study and open-label extension of a double-blind study.
    Duric, B
    Marjanovic, B
    Zamurovic, D
    Jovic, N
    Rajcic, N
    EPILEPSIA, 1999, 40 : 156 - 156
  • [24] Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial
    Terauchi, Yasuo
    Tamura, Masahiro
    Senda, Masayuki
    Gunji, Ryoji
    Kaku, Kohei
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1397 - 1407
  • [25] Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
    Rendell, Marc
    Chrysant, Steven G.
    POSTGRADUATE MEDICINE, 2011, 123 (04) : 183 - 186
  • [26] Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
    Nobuya Inagaki
    Shin-ichi Harashima
    Nobuko Maruyama
    Yutaka Kawaguchi
    Maki Goda
    Hiroaki Iijima
    Cardiovascular Diabetology, 15
  • [27] Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
    Inagaki, Nobuya
    Harashima, Shin-ichi
    Maruyama, Nobuko
    Kawaguchi, Yutaka
    Goda, Maki
    Iijima, Hiroaki
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [28] Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    DIABETES CARE, 2014, 37 (06) : 1650 - 1659
  • [29] Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
    Kadokura, Takeshi
    Akiyama, Noriko
    Kashiwagi, Atsunori
    Utsuno, Atsushi
    Kazuta, Kenichi
    Yoshida, Satoshi
    Nagase, Itsuro
    Smulders, Ronald
    Kageyama, Shigeru
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (01) : 50 - 56
  • [30] Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    Jeong, In-Kyung
    Choi, Kyung Mook
    Han, Kyung Ah
    Kim, Kyoung-Ah
    Kim, In Joo
    Han, Seung Jin
    Lee, Won Young
    Yoo, Soon Jib
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5065 - 5077
12345